Cargando…
Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
Human epidermal growth factor receptor 3 (HER3) expression in lung and breast cancers has a negative impact on survival. Patritumab, a human anti‐HER3 mAb, has shown anticancer activity in preclinical models. This study examined the safety and pharmacokinetics of patritumab in combination with trast...
Autores principales: | Mukai, Hirofumi, Saeki, Toshiaki, Aogi, Kenjiro, Naito, Yoichi, Matsubara, Nobuaki, Shigekawa, Takashi, Ueda, Shigeto, Takashima, Seiki, Hara, Fumikata, Yamashita, Tomonari, Ohwada, Shoichi, Sasaki, Yasutsuna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084669/ https://www.ncbi.nlm.nih.gov/pubmed/27452985 http://dx.doi.org/10.1111/cas.13017 |
Ejemplares similares
-
Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2014) -
Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer
por: TAKASHIMA, SEIKI, et al.
Publicado: (2015) -
Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
por: Saeki, Toshiaki, et al.
Publicado: (2016) -
Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010) -
Metastatic Breast Cancer to the Stomach Resembling Early Gastric Cancer
por: Hara, Fumikata, et al.
Publicado: (2010)